Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kidmin is a specialized 7.2% intravenous amino acid solution developed by Otsuka Pharmaceutical Factory for patients with acute or chronic renal failure. The formulation is specifically designed to address the nutritional requirements of kidney failure patients, particularly those undergoing hemodialysis or peritoneal dialysis who experience hypoproteinemia or malnutrition. It contains a balanced mixture of essential and non-essential amino acids, with a high concentration of branched-chain amino acids (BCAAs)—L-leucine, L-isoleucine, and L-valine—which function to inhibit muscle protein breakdown and stimulate muscle protein synthesis. As a parenteral nutrition product, Kidmin provides the necessary building blocks for protein metabolism without targeting a specific receptor or enzyme in the traditional pharmacological sense.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kidmin.